Antibody Therapeutics

First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region

• Abstract
• Supplementary data

rAbDesFlow: A novel workflow for computational recombinant antibody design for healthcare engineering

• Abstract
• Supplementary data

HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study

• Abstract
• Supplementary data

Preclinical studies of BB-1701, a HER2-targeting eribulin-containing ADC with potent bystander effect and ICD activity

• Abstract
• Supplementary data

Fc engineering by monoclonal mammalian cell display for improved affinity and selectivity towards FcγRs

• Abstract
• Supplementary data

Correction to: Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

• Extract

An integrated database of experimentally validated major histocompatibility complex epitopes for antigen-specific cancer therapy

• Abstract
• Supplementary data

Protein language models enable prediction of polyreactivity of monospecific, bispecific, and heavy-chain-only antibodies

• Abstract
• Supplementary data

A case study of a bispecific antibody manufacturability assessment and optimization during discovery stage and its implications

• Abstract
• Supplementary data

A new mechanism of antibody diversity: formation of the natural antibodies containing LAIR1 and LILRB1 extracellular domains

• Abstract

Correction to: Role of antibody engineering in generation of derivatives starting from MOv19 MAb: 40 years of biological/therapeutic tools against folate receptor alfa

• Extract

A VHH single-domain platform enabling discovery and development of monospecific antibodies and modular neutralizing bispecifics against SARS-CoV-2 variants

• Abstract
• Supplementary data

Structure and function of therapeutic antibodies approved by the US FDA in 2023

• Abstract

Development of a novel humanized anti-TSLP monoclonal antibody HZ-1127 with anti-allergic diseases and cancer potential

• Abstract
• Supplementary data

Reforming solid tumor treatment: the emerging potential of smaller format antibody-drug conjugate

• Abstract

Correction to: Bringing cell therapy to tumors: considerations for optimal CAR binder design

• Extract

Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA

• Abstract
• Supplementary data

Further accelerating biologics development from DNA to IND: the journey from COVID-19 to non-COVID-19 programs

• Abstract

Effects of Fc glycosylation on the activity of WNT mimetic agonistic antibodies

• Abstract
• Supplementary data